Received May 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 1 | u7767aa | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | y005351 | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | y009786 | — |
patient received ROTATEQ, VAXELIS and VAXNEUVANCE at 41 days instead of the recommended 42 day vaccination schedule; No adverse event; This non-serious spontaneous safety report, with reference number 02775781 (interaction number: 02775778), was received by partner on 24-MAR-2025 and forwarded on 25-MAR-2025 from other health professional. Due to the nature of the event, the causality between the event 'patient received ROTATEQ, VAXELIS and VAXNEUVANCE at 41 days instead of the recommended 42-day vaccination schedule' and Vaxelis was not applicable. Further information is expected. Significant follow-up information was received on 10-APR-2025 from a health professional. Due to the nature of the event, the causality between the event "patient received ROTATEQ, VAXELIS and VAXNEUVANCE at 41 days instead of the recommended 42-day vaccination schedule" and Vaxelis was not applicable. No further information is expected.
Prophylaxis